In the latest market close, DaVita HealthCare (DVA) reached $139.96, with a +1.46% movement compared to the previous day. The stock exceeded the S&P 500, which registered a gain of 1.08% for the day. At the same time, the Dow added 0.32%, and the tech-heavy Nasdaq gained 1.58%. Investors should also take note of any recent adjustments to analyst estimates for DaVita HealthCare. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Hence, positive alterations in estimat ...

When calling in, please provide the operator the password "Earnings" and provide your name and company affiliation. Investors unable to listen to the conference call will be able to access a replay via our website at investors.davita.com. There will be no telephone replay. This call is also being webcast and can be accessed at the DaVita IR web page. You can join this call as follows: DaVita (NYSE: DVA) is a health care provider focused on transforming care delivery to improve quality of life for patients g ...

Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system. Meanwhile, DVA's PEG ratio is currently 1.04. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. The Medical - Outpatient and Home Healthcare was holding an averag ...

Denver, CO-headquartered DaVita, is a leading provider of dialysis services in the United States to patients suffering from chronic kidney failure, also known as end-stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services, primarily in dialysis centers and contracted hospitals across the country. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease man ...

New York, United States, July 16, 2024 (GLOBE NEWSWIRE) -- As per the Latest Report by Straits Research, the global renal denervation devices market size was valued at USD 54.26 million in 2023. It is estimated to reach an expected value of USD 387 million by 2032, growing at a CAGR of 37.2% during the forecast period (2024–2032). Rising Prevalence of Hypertension Propels the Renal Denervation Devices Market It is anticipated that the number of individuals suffering from hypertension will increase as the gl ...

Company Performance - DaVita HealthCare (DVA) shares experienced a loss of 2.97% over the previous month, underperforming the Medical sector's loss of 1.99% and the S&P 500's gain of 4.34% [1] - In the latest trading session, DaVita HealthCare closed at $137.92, reflecting a +0.39% move from the prior day, outperforming the S&P 500's daily gain of 0.07% [6] - The upcoming earnings disclosure is projected to show earnings of $2.47 per share, indicating year-over-year growth of 18.75%, with a revenue estimate of $3.16 billion, representing a 5.43% rise from the same quarter last year [7] Financial Estimates - For the entire fiscal year, earnings are projected at $9.62 per share and revenue at $12.74 billion, reflecting changes of +13.58% and +4.97% from the prior year, respectively [2] - DaVita HealthCare currently has a Forward P/E ratio of 14.27, which is below the industry average Forward P/E of 22.5, indicating it is trading at a discount compared to its peers [9] Analyst Insights - Recent changes to analyst estimates for DaVita HealthCare are important as they reflect short-term business trends, with positive revisions indicating analysts' confidence in the company's performance [8] - The Zacks Rank system rates DaVita HealthCare at 2 (Buy), with a track record of delivering an average annual return of +25% for stocks rated 1 since 1988 [11] Industry Context - The Medical - Outpatient and Home Healthcare industry, which includes DaVita HealthCare, has a current Zacks Industry Rank of 52, placing it in the top 21% of over 250 industries [12]

Company Overview - DaVita HealthCare (DVA) ended the latest trading session at $142.16, reflecting a -0.53% adjustment from the previous day's close, underperforming the S&P 500's 0.16% gain [3] - Over the last month, DaVita's shares decreased by 0.52%, while the Medical sector gained 2.32% and the S&P 500 increased by 3.22% [3] Earnings Performance - DaVita is expected to report an EPS of $2.47, indicating an 18.75% growth compared to the same quarter last year [4] - The consensus estimate for revenue is $3.16 billion, showing a 5.43% increase compared to the year-ago quarter [4] - For the entire year, the Zacks Consensus Estimates forecast earnings of $9.62 per share and revenue of $12.74 billion, reflecting changes of +13.58% and +4.97% respectively compared to the previous year [5] Analyst Estimates and Rankings - Recent changes to analyst estimates for DaVita HealthCare suggest positive business outlooks, as these revisions often reflect short-term business dynamics [5] - DaVita currently holds a Zacks Rank of 2 (Buy), with no change in the Zacks Consensus EPS estimate over the past month [6] Valuation Metrics - DaVita HealthCare is trading at a Forward P/E ratio of 14.85, which is a discount compared to the industry average Forward P/E of 23.18 [7] - The company has a PEG ratio of 1.09, compared to the industry average PEG ratio of 1.96 [7] Industry Context - The Medical - Outpatient and Home Healthcare industry, which includes DaVita, has a Zacks Industry Rank of 27, placing it in the top 11% of over 250 industries [8] - The Zacks Industry Rank measures the strength of industry groups based on the average Zacks Rank of individual stocks, indicating that top-rated industries outperform the bottom half by a factor of 2 to 1 [8]

Company Overview - DaVita Inc. is a leading provider of dialysis services in the U.S. for patients suffering from chronic kidney failure, operating kidney dialysis centers and providing related medical services primarily in dialysis centers and contracted hospitals across the U.S. [10] - The company's services include outpatient dialysis services, hospital inpatient dialysis services, and ancillary services such as ESRD laboratory services and disease management services [10]. Investment Ratings - DaVita Inc. holds a Zacks Rank of 2 (Buy) and has a VGM Score of A, indicating strong potential for investment [11]. - The company is also considered a top pick for growth investors, with a Growth Style Score of B, forecasting year-over-year earnings growth of 13.6% for the current fiscal year [11]. Earnings Estimates - In the last 60 days, three analysts have revised their earnings estimates upwards for fiscal 2024, with the Zacks Consensus Estimate increasing by $0.39 to $9.62 per share [11]. - DaVita boasts an average earnings surprise of 29.4%, indicating a strong performance relative to expectations [11]. Conclusion - With a solid Zacks Rank and top-tier Growth and VGM Style Scores, DaVita Inc. is recommended for investors' consideration [12].

Denver, CO-headquartered DaVita is a leading provider of dialysis services in the United States to patients suffering from chronic kidney failure, also known as end-stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services, primarily in dialysis centers and contracted hospitals across the country. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease mana ...

Thus, at the moment, investing in service-oriented companies like CareCloud, Inc. (CCLD) , DaVita Inc. (DVA) , RadNet, Inc. (RDNT) , SkyWest, Inc. (SKYW) and American Express Company (AXP) seems judicious. The NMI, incidentally, had fallen into the contraction territory for the first time in April since December 2022. Any reading below the 50% mark indicates a contraction. The business activity index increased to 61.2% in May from 50.9% in April and expanded for the 48th successive month. The index has notc ...